A share price of Kronos Bio Inc [KRON] is currently trading at $0.85, down -0.12%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KRON shares have gain 3.03% over the last week, with a monthly amount drifted -8.60%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Kronos Bio Inc [NASDAQ: KRON] stock has seen the most recent analyst activity on November 14, 2024, when TD Cowen downgraded its rating to a Hold. Previously, Piper Sandler downgraded its rating to Neutral on November 14, 2024, and dropped its price target to $1. On September 14, 2022, Berenberg initiated with a Buy rating and assigned a price target of $12 on the stock. H.C. Wainwright initiated its recommendation with a Buy and recommended $35 as its price target on June 24, 2021. Piper Sandler started tracking with a Overweight rating for this stock on November 03, 2020, and assigned it a price target of $50. In a note dated November 03, 2020, Jefferies initiated an Buy rating and provided a target price of $36 on this stock.
Kronos Bio Inc experienced fluctuations in its stock price throughout the past year between $0.69 and $1.60. Currently, Wall Street analysts expect the stock to reach $1.63 within the next 12 months. Kronos Bio Inc [NASDAQ: KRON] shares were valued at $0.85 at the most recent close of the market. An investor can expect a potential return of 91.76% based on the average KRON price forecast.
Analyzing the KRON fundamentals
Trailing Twelve Months sales for Kronos Bio Inc [NASDAQ:KRON] were 9.86M which represents 158.45% growth. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -8.14%, Pretax Profit Margin comes in at -8.68%, and Net Profit Margin reading is -8.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.65 and Total Capital is -0.6. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8006 points at the first support level, and at 0.7512 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8988, and for the 2nd resistance point, it is at 0.9476.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kronos Bio Inc [NASDAQ:KRON] is 8.32. Further, the Quick Ratio stands at 8.32, while the Cash Ratio is 4.87. Considering the valuation of this stock, the price to sales ratio is 5.20, the price to book ratio is 0.46.
Transactions by insiders
Recent insider trading involved BISCHOFBERGER NORBERT W, PRESIDENT & CEO, that happened on Jun 27 ’24 when 0.41 million shares were purchased. PRESIDENT & CEO, BISCHOFBERGER NORBERT W completed a deal on Jun 28 ’24 to buy 0.2 million shares. Meanwhile, PRESIDENT & CEO BISCHOFBERGER NORBERT W bought 1.38 million shares on Jun 10 ’24.
